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Table 3
DonorDBY DonorUTY DonorZFY DonorEIF1AY DonorRPS4Y
　 - + P - + P - + P - + P - + P
Recipient - 38 7 0.2 31 13 0.28 55 4 0.29 56 1 >0.99 44 5 0.72
post-HCT + 32 13 　 27 19 　 31 0 　 33 0 　 38 3 　
Abstracts / Biol Blood Marrow Transplant 20 (2014) S45eS56 S55adoptive transfer of HY seropositivity from female donors to
male recipients (Table 3).
Conclusion: Half of female donors were HY-seropositive, but
there were no enough evidence to suggest that the HY
sensitization can predict clinical outcome. In fact, we pro-
vided little evidence of adoptive HY B-cell immunity transfer.
On-going studies will relate female HY sensitization to parity
and age. The absence of adoptive immune transfer might
raise a concern for the efﬁcacy of donor vaccination strate-
gies to augment GVL beneﬁt.52
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The immunosuppressive function of IL10 producing regula-
tory B cells (Bregs) has been shown in several murine models
of inﬂammation and autoimmune disease. However, there is
a paucity of data regarding the existence of an equivalent
regulatory B cell subset in humans and their relevance in the
pathogenesis of chronic graft-versus-host disease (cGVHD)
remains unknown. Here, we explored the regulatory
properties of peripheral blood (PB)-derived human B cell
subsets and their role in cGVHD. Using intracellular cytokine
staining following in vitro stimulation with CD40 ligand, we
showed that the majority of IL-10 producing B cells in
healthy donors are found within the CD24hiCD38hi transi-
tional and CD19+IgM+CD27+ memory B cell subsets. Sort-
puriﬁed IgM memory and transitional B cells suppressed the
proliferation, as well as the release of IFN-g by CD3/CD28
stimulated CD4+ T cells. The inhibitory effect of IgM memory
and transitional B cells on CD4+ T cell proliferation was cell
dose dependent with the highest suppression was observed
at a ratio of 1:1. These data suggest that human PB transi-
tional and IgM memory B cells are endowed with suppres-
sive function. This suppression was mediated partially via
the provision of IL-10, but not TGF-ß, which we assessed by
antibody blockade experiments. Additionally, the suppres-
sive capacity of the B cell subsets was reversed by the addi-
tion of CD80 and CD86 mAbs. Using transwell experiments,
we further determined that the suppressive function of Bregs
is also partly dependent on direct T cell/B cell contact.
Although blockade of IL-10 and IL-10R, CD80 and CD86 andseparation of B cells and T cells by a transwell membrane
individually did not completely reverse the suppressive
ability of transitional and IgMmemory B cells, a combination
of these factors sufﬁciently reversed the ability of Breg
subsets to suppress CD4+ Tcell proliferation. Thus, analogous
to murine experimental models the suppressive effect of
human Breg cells involves both the release of IL-10 and
co-receptor interaction. Additionally, Breg cells isolated from
patients with cGVHD were refractory to CD40 stimulation
and produced less IL-10 when compared to patients without
cGVHD post-SCT and healthy controls. Likewise, the absolute
number of IL-10 producing B cells was signiﬁcantly lower in
cGvHD patients compared to patients without cGVHD and
healthy controls (p¼0.007), supporting the existence of both
a qualitative and quantitative defect in IL-10 producing
B cells in cGvHD.
Our combined studies provide important new data deﬁning
the phenotype of B cell populations enriched in regulatory
B cells in healthy humans and provide evidence of altered
cellular function within such cells that may impact a broad
range of deﬁciencies in immune regulatory cell function in
cGvHD post transplant patients.
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Background: Commensal gut microbiota have been im-
plicated in initiating and perpetuating intestinal graft versus
host disease (iGVHD), but its role remains controversial. Recent
murine studies have shown that iGVHD results in destruction
of intestinal mucosal immune defenses resulting in expansion
of pro-inﬂammatory bacteria (Enterobacteriaceae, ENTERO),
and by prophylactically treatingmicewith oral antibiotics that
suppress growth of ENTERO, iGVHD was signiﬁcantly
improved1. Furthermore, small-chain fatty acid producing
(SCFA) Clostridia have been shown to induce colonic Treg cells,
to dampen gut inﬂammation, and to cure IBD in mice2. But
theseﬁndingshavenot beenobservedor replicated inhumans.
Methods: Stool samples were collected on a weekly basis
from pediatric allogeneic BMT patients from 7/26/11 e 9/30/
13. Bacterial and fungal gDNA was isolated from fecal spec-
imens. Amplicons for 16S rRNAV4 variable region and fungal
ITS region were generated and sequenced on Roche 454
GS-FLX sequencer and Illumina HiSeq2000 respectively.
Sequencing data was analyzed using QIIME software. The
abundance of speciﬁc intestinal bacterial groups was deter-
mined by qPCR using group-speciﬁc 16S rRNA gene primers.
For patients undergoing intestinal biopsy for suspicion of
iGVHD (abdominal pain, diarrhea), additional pieces of
intestine were obtained for transcription proﬁling experi-
ments using Illumina HumanHT12 V4 Expression BeadChips.
Clinical characteristics (i.e. conditioning regimens, speciﬁc
antibiotic use, immunosuppression, etc) were recorded.
Figure 1. Improved GHVD-free Survival by Blocking CD28
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terial groupqPCRwasperformedon10patients (4 iGVHD, 6no
GVHD). As evidenced by 16S rRNA sequencing, only patients
with iGVHD developed signiﬁcant expansion of ENTERO and a
signiﬁcant decrease in SCFA Clostridia prior to the diagnosis of
iGVHD. Bacterial group qPCR conﬁrmed these ﬁndings: pa-
tients with GVHD had signiﬁcantly higher ENTERO (p< 0.01,
Mann Whitney) and signiﬁcantly lower EREC and CLEPT
(subgroups of the SCFA Clostridia) (P<0.01) than non-GVHD
counterparts. Of the clinical characteristics recorded, clinda-
mycin treatment, which is effective against Clostrida spp, was
the most strongly associated with the development of iGVHD
Conclusion: Expansion of pro-inﬂammatory ENTERO and
decreases in anti-inﬂammatory Clostridia (CLEPT and EREC)
are associatedwith iGVHD in pediatric BMT patients. Medical
therapies such as chemotherapy and/or antibiotics may
disturb the baseline gut microbiota and make certain
patients predisposed to the development of iGVHD. Real-
timemonitoring of the gut microbiota (bacterial group qPCR)
has great potential as a biomarker for iGVHD.
1. Eriguchi et al. Blood. Jul 5 2012;120(1):223-231.
2. Atarashi et al. Nature. Aug 8 2013;500(7461):232-236
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Introduction: We have previously shown, using a non-hu-
man primate (NHP) model, that inhibition of CD28:CD80/86
costimulation with CTLA4-Ig could prevent GVHD, and this
strategy is now being tested in a Phase 2 clinical trial. Despite
the potential efﬁcacy of CTLA4-Ig, there is concern that it may
have off-target effects, given its inhibition of both (+) CD28
signaling and (-) CTLA4 signaling. In order to speciﬁcally target
CD28, we have developed an antagonistic humanized anti-
CD28 monovalent Fab’ antibody (FR104). Here we investigate
the efﬁcacy and mechanism of action of FR104 in NHP, to
potentially facilitate its most rapid clinical translation.
Methods: NHP underwent MHC-mismatched HCT after
myeloablative TBI. They were transplanted with GCSF-mobi-
lized PBSCs (4  1x108 TNC/kg and 2  0.5x 107 CD3+ T
cells/kg). GVHD prophylaxis was with FR104 monotherapyFigure 2. CD28-blockade-mediated Inhibition of GVHD Correlates with Control of CD8
Post-transplant. B. Inhibition of CD8+ proliferation correlates with GVHD-free surviv(5mg/kg/wk IV, resulting in <1% CD28 expression) or with
FR104 +mTOR inhibitionwith rapamycin, andwere compared
to two controls groups (untreated recipients and rapamycin
monotherapy). Clinical and histologic GVHD was monitored
and longitudinal immunologic analysis performed.
Results: Untreated controls (n ¼ 5) developed rapid, severe
AGVHD (MST¼7 d). Rapamycin alone (n ¼ 6) partially
protected recipients, with GI-predominant AGVHD (MST ¼
14 d, Fig. 1). FR104 monotherapy showed statistically
signiﬁcant prolongation in survival (MST ¼ 27 days, n ¼ 3)
compared to rapamycin (p ¼ 0.05) and untreated controls
(p¼0.02), with breakthrough GVHD occurring in two animals
(liver and skin). In contrast, FR104 + rapamycin (n ¼ 3)
controlled GVHD, with all recipients reaching the timed
terminal analysis at day +33-35 without clinical disease
(p ¼ 0.017 vs. untreated, p ¼ 0.013 versus rapamycin alone).
Our previous work has documented a major role for T cell
proliferation (by Ki-67 expression) in GVHD, with untreated
controls demonstrating rampant CD8+ proliferation (89  5%
Ki-67+ CD8+ T cells at terminal analysis (d +6) vs. 4% pre-
transplant, Fig. 2A). Rapamycin and FR104 monotherapy both
partially controlled proliferation (9% 4% and 14% 8%Ki-67+
CD8+ on d +6) with rapamycin + FR104 combination therapy
resulting in further control (3.5% 0.3% Ki-67+ CD8+ on d +6).
Moreover, the degree of CD8+ proliferation correlated closely
with GVHD-free survival (Fig. 2B), suggesting that Ki-67
expression may be a predictive biomarker of this disease.
Implications: These results show that speciﬁc blockade of
CD28 can inhibit NHP GVHD and when combined with
rapamycin, can effectively control this disease for the length of
dual therapy. Importantly, clinical control of GVHDwith FR104
correlatedwithnormalizationof Tcell proliferation.Our results
suggest that selective CD28 blockade may be a safe and effec-
tive adjunctive strategy to inhibit GVHD-associated T cell acti-
vation, and is deserving of clinical evaluation in patients
undergoing HCT.+ T cell Proliferation. A. % of Proliferating CD8þ T cells Measured Longitudinally
al.
